Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization.

Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ.

Clin Cancer Res. 2005 Apr 1;11(7):2576-82.

2.

Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.

Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ.

Cancer Immunol Immunother. 2004 Nov;53(11):978-86. Epub 2004 Jun 17.

PMID:
15197496
3.

A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer.

Menon AG, Fleuren GJ, Alphenaar EA, Jonges LE, Janssen van Rhijn CM, Ensink NG, Putter H, Tollenaar RA, van de Velde CJ, Kuppen PJ.

Cancer Immunol Immunother. 2003 Feb;52(2):121-6. Epub 2003 Jan 30.

PMID:
12594576
4.

The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma.

Hagenaars M, Koelemij R, Ensink NG, van Eendenburg JD, van Vlierberghe RL, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Clin Exp Metastasis. 2000;18(4):281-9.

PMID:
11448057
5.

Caspase-3 activity as a prognostic factor in colorectal carcinoma.

Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ, van de Velde CJ, Morreau H, Kuppen PJ.

Lab Invest. 2001 May;81(5):681-8.

6.

Administration of BiMAb-retargeted T cells in a rat hepatic metastases colon tumour model results in T-cell tumour infiltration independent of the route of administration.

Koelemij R, Hagenaars M, Ensink NG, Eggermont AM, Van De Velde CJ, Fleuren GJ, Kuppen PJ.

Scand J Immunol. 2001 Mar;53(3):277-81.

7.

The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?

Hagenaars M, Ensink NG, Basse PH, Hokland M, Nannmark U, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Clin Exp Metastasis. 2000;18(2):189-96.

PMID:
11235995
8.

The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood.

Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ, Fleuren GJ, Nannmark U, Kuppen PJ.

Scand J Immunol. 2001 Feb;53(2):103-10.

9.

NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis.

Jonges LE, Giezeman-Smits KM, van Vlierberghe RL, Ensink NG, Hagenaars M, Joly E, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Immunobiology. 2000 Nov;202(4):326-38.

PMID:
11131150
10.

Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells.

Geutskens SB, van der Eb MM, Plomp AC, Jonges LE, Cramer SJ, Ensink NG, Kuppen PJ, Hoeben RC.

Gene Ther. 2000 Aug;7(16):1410-6.

11.

Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model.

Hagenaars M, Ensink NG, Eggermont AM, van der Velde EA, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Cancer Immunol Immunother. 2000 Jan;48(10):561-8.

PMID:
10630308
12.

The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.

Hagenaars M, Ensink NG, Jonges LE, Chambers WH, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Immunobiology. 1999 Feb;200(1):31-48.

PMID:
10084694
13.

Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses.

Hagenaars M, Zwaveling S, Kuppen PJ, Ensink NG, Eggermont AM, Hokland ME, Basse PH, van de Velde CJ, Fleuren GJ, Nannmark U.

Int J Cancer. 1998 Dec 9;78(6):783-9.

14.

Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.

Hagenaars M, Ensink NG, Koelemij R, Basse PH, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Int J Cancer. 1998 Jan 19;75(2):233-8.

15.

The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells.

Giezeman-Smits KM, Kuppen PJ, Ensink NG, Eggermont AM, Stals F, Wonigeit K, Fleuren GJ.

Immunobiology. 1996 Aug;195(3):286-99.

PMID:
8877403
16.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608

Supplemental Content

Loading ...
Support Center